Wall Street Experts
ver. ZuMIgo(08/25)
Mereo BioPharma Group plc
Rachunek Zysków i Strat
Przychody TTM (mln): 0
EBIT TTM (mln): -38
| index |
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
| Rok finansowy |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Przychód (mln) |
0 |
-3 |
0 |
-0 |
0 |
36 |
2 |
10 |
0 |
| Przychód Δ r/r |
0.0% |
-inf% |
-100.0% |
-inf% |
-422.1% |
9178.4% |
-95.9% |
563.6% |
-100.0% |
| Marża brutto |
-inf% |
1153.4% |
-inf% |
19450.8% |
-4059.5% |
50.9% |
37.9% |
74.3% |
0.0% |
| EBIT (mln) |
-36 |
-45 |
-35 |
-40 |
-38 |
-21 |
-44 |
-28 |
-47 |
| EBIT Δ r/r |
0.0% |
25.2% |
-22.3% |
12.2% |
-4.9% |
-44.3% |
108.1% |
-34.8% |
66.7% |
| EBIT (%) |
0.0% |
1379.0% |
0.0% |
32391.0% |
-9559.5% |
-57.4% |
-2891.1% |
-284.2% |
nan |
| Koszty finansowe (mln) |
0 |
1 |
2 |
3 |
6 |
4 |
3 |
3 |
-1 |
| EBITDA (mln) |
-38 |
-44 |
-35 |
-38 |
-38 |
-20 |
-42 |
-24 |
-47 |
| EBITDA(%) |
0.0% |
1352.7% |
0.0% |
30789.3% |
-9548.3% |
-55.7% |
-2791.1% |
-239.5% |
nan |
| Podatek (mln) |
-5 |
-8 |
-5 |
-6 |
-3 |
2 |
-2 |
-1 |
0 |
| Zysk Netto (mln) |
-28 |
-39 |
-32 |
-35 |
-164 |
13 |
-34 |
-29 |
-43 |
| Zysk netto Δ r/r |
0.0% |
36.7% |
-17.4% |
8.8% |
369.6% |
-107.8% |
-368.7% |
-13.8% |
46.8% |
| Zysk netto (%) |
0.0% |
1181.0% |
0.0% |
28560.7% |
-41635.6% |
34.9% |
-2269.1% |
-294.7% |
nan |
| EPS |
-3.17 |
-2.81 |
-2.25 |
-1.95 |
-2.42 |
0.12 |
-0.28 |
0.0 |
-0.0585 |
| EPS (rozwodnione) |
-3.17 |
-2.81 |
-2.25 |
-1.95 |
-2.41 |
0.11 |
-0.28 |
0.0 |
-0.0585 |
| Ilośc akcji (mln) |
9 |
14 |
14 |
18 |
68 |
106 |
121 |
659,454 |
740 |
| Ważona ilośc akcji (mln) |
9 |
14 |
14 |
18 |
68 |
111 |
121 |
659,454 |
740 |
| Waluta |
GBP |
GBP |
GBP |
GBP |
GBP |
GBP |
GBP |
USD |
USD |